Veru (NASDAQ: VERU) Chief Scientific Officer receives 160,000 stock options grant

Rhea-AI Filing Summary

VERU INC. disclosed that Chief Scientific Officer K. Gary Barnette received a compensation-related grant of stock options. The award covers 160,000 options to acquire Veru common shares at an exercise price of $2.25 per share, with all options held directly after the grant.

According to the vesting terms, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. This filing reflects an equity incentive grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BARNETTE K GARY

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	160,000	$0.00	--

Holdings After Transaction: Common Stock Option — 160,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 160,000 options Exercise price: $2.25 per share Expiration date: May 4, 2036 +2 more

5 metrics

Options granted 160,000 options Grant of common stock options to CSO

Exercise price $2.25 per share Strike price for Veru common stock options

Expiration date May 4, 2036 Option term end date

Vesting dates May 4, 2027 / 2028 / 2029 One-third of options vest on each date

Underlying shares 160,000 shares Underlying Veru common stock tied to the options

Key Terms

Common Stock Option, exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Common Stock Option financial

"security_title: "Common Stock Option""

exercise price financial

"conversion_or_exercise_price: "2.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest financial

"Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARNETTE K GARY

(Last) (First) (Middle)

2916 N. MIAMI AVENUE

SUITE 1000

(Street)

MIAMI FLORIDA 33127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERU INC. [ VERU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$2.25	05/04/2026		A		160,000		05/04/2027(1)	05/04/2036	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029.

	/s/ Phil R. Greenberg, via Power of Attorney	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What stock options did VERU (VERU) grant to its Chief Scientific Officer?

VERU granted its Chief Scientific Officer 160,000 stock options as equity compensation. These options allow the holder to buy Veru common stock at $2.25 per share, subject to a multi-year vesting schedule and a final expiration date in 2036.

What is the exercise price of the new VERU (VERU) stock options?

The granted options have an exercise price of $2.25 per share. This means the Chief Scientific Officer can purchase Veru common stock at $2.25 once options vest, regardless of future market price, until the options expire in 2036, if vesting conditions are met.

How do the VERU (VERU) options granted to the Chief Scientific Officer vest?

The options vest in three equal installments over three years. One-third of the 160,000 options vests on each of May 4, 2027, May 4, 2028, and May 4, 2029, aligning the award with multi-year service and performance horizons.

When do the recently granted VERU (VERU) stock options to the CSO expire?

The options granted to the Chief Scientific Officer expire on May 4, 2036. After that date, any unexercised options become worthless, even if vested, so the holder must exercise vested options before this expiration to acquire Veru common shares.

Is the VERU (VERU) Chief Scientific Officer buying or selling shares in this Form 4?

The Form 4 reflects an option grant, not an open-market trade. The Chief Scientific Officer acquired 160,000 stock options as compensation, with no reported stock purchases or sales in the market as part of this specific filing.

How many VERU (VERU) options does the Chief Scientific Officer hold after this grant?

Following this transaction, the filing shows the Chief Scientific Officer holding 160,000 stock options directly. These options are tied to Veru common stock, carry a $2.25 exercise price, and vest in three annual installments starting in 2027.